SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it will present the first preclinical data on ATG-207 (αCD3-TGF-β bifunctional fusion protein) in a poster presentation at the 2026 European Congress of Rheumatology (EULAR 2026), taking place from June 3 to 6 at Excel London in the United Kingdom. ATG-207 represents Antengene's first disclosed program from its T cell-mediated autoimmune disease research efforts.
T cell-mediated autoimmune diseases are characterized by sustained activation of pathogenic effector T cells and insufficient or unstable regulatory T cell function, resulting in an inability to establish durable immune tolerance. These diseases remain an area of significant unmet medical need, as existing anti-inflammatory therapies may not sufficiently eliminate persistent pathogenic effector T cells or restore long-term immune balance. ATG-207 is designed to address these challenges through a differentiated dual mechanism that integrates CD3-mediated T cell modulation with localized, TGFβRIII-biased TGF-β activity, with the goal of selectively suppressing pathogenic T cells while promoting regulatory T cell induction and immune tolerance.
